Have you been prescribed Docetaxel for treatment of advanced metastatic prostate cancer?
Thursday, 28th February 2019
A new radioactive labelled trace called Prostate Specific Membrane Antigen (PSMA) has been developed which is very sensitive to prostate cancer cells wherever they may be in the body.
If you have been prescribed docetaxel for treatment of advanced metastatic prostate cancer and would you be interested in taking part in a medical imaging trial that would involve having three extra scans using the PSMA alongside the usual medical imaging tests, please get in touch with Professor Barnes.
She would like to speak to you if you would be willing to:
- Discuss and answer questions about the role of nuclear medicine in your treatment;
- Discuss personal experiences with nuclear medicine tests, that you are willing to share;
- Help UCL to design a plan that includes 3 extra scans that patients would be willing to participate in.
For more detail about the trial, please view the attached article from Professor Barnes.
For information regarding eligibility criteria, and to register your interest please contact Professor Barnes directly at:
Anna Barnes, PhD, CSci, FIPEM
Clinical Scientist (PETMRI), Nuclear Medicine
HEE/NIHR-Senior Clinical Lecturer, CMI, UCL
UCL Hospitals NHS Foundation Trust
235 Euston Road | London NW1 2BU | UK
Voluntary Services Exhibition for Trainee GPs
28 Mar 2019 13:30–14:45
PSA Testing Chester Masonic Hall Christleton
30 Mar 2019 09:30–12:30
PSA Testing at Nantwich Civic Hall
13 Apr 2019 09:30–12:30
Wellbeing Event for NHS staff
1 May 2019 10:00–15:00
Group AGM at Leighton Hospital, Crewe
11 May 2019 10:00–12:00
New Podcast from Pain Concern
11 Mar 2019